Abstract
Transcriptional metabolic profiling young onset colorectal cancer (CRC) patients
Journal of clinical oncology, Vol.41(16_suppl), pp.3509-3509
06/01/2023
DOI: 10.1200/JCO.2023.41.16_suppl.3509
Abstract
3509
Background: Patients diagnosed with colorectal cancer (CRC) at age < 50 years typically present with more advanced disease, resulting in poor therapeutic response and clinical outcomes. Therefore, there is an unmet need to understand the differences in transcriptional profiles between younger (<50) and older ( > 50) CRC patients. Methods: Using TCGA (n = 397; > 50 = 349; < 50 = 48) and Oncology Research Information Exchange network (ORIEN) CRC datasets (n = 460; > 50 = 364 ; < 50 = 96), patients were separated into younger and older populations. Baseline characteristics of the patients in this analysis are provided in the accompanying table. Subsequently, their transcriptional profiles were compared and assessed via differential gene expression analysis (DESeq2), gene set enrichment analysis (GSEA), immune deconvolution (TIMER2.0), and metabolic pathway analysis (MetaPhOR). These pathways were then mapped to assess transcriptional dysregulation, and patterns of predicted metabolic flux. Results: Comparisons of older and younger groups revealed a large number of significantly differentially expressed transcripts (n = 2629), enrichment in younger groups of metabolic pathways (amino acids and lipids), oncogenes (MYC targets and NRAS targets), and cellular processes. In the older group we found enrichment of methylation and histone modification, immune response, and other metabolic pathways, like androgens. Metabolic pathway analysis revealed consistent alterations in steroid hormone metabolism and kynurenine metabolism, which were largely upregulated in the over 50 group. Additionally, pathways associated with response to both CTLA4 and PDL1 treatment were largely upregulated in the over 50 group. This transcriptional signature may be associated with a pre-disposition to different clinical outcomes and therapeutic response for agents targeting these pathways. Conclusions: Overall, this study has revealed differences in transcriptional metabolic profiles and other drivers of disease, as well as immune profiles, between younger and older CRC populations. This biology should be explored in the future, as new avenues for treatment in younger CRC populations. [Table: see text]
Details
- Title: Subtitle
- Transcriptional metabolic profiling young onset colorectal cancer (CRC) patients
- Creators
- Deepak Vadehra - Roswell Park Comprehensive Cancer CenterSpencer Rosario - Roswell Park Comprehensive Cancer CenterJianmin Wang - Roswell Park Comprehensive Cancer CenterYali Zhang - Roswell Park Comprehensive Cancer CenterHua-Hsin Hsiao - Roswell Park Comprehensive Cancer CenterJill Kolesar - University of KentuckyPatricia McDonald - Moffitt Cancer CenterDaniel Spakowicz - The Ohio State UniversitySami Ibrahimi - University of Oklahoma Health Sciences CenterFred Tabung - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteDwight Hall Owen - The Ohio State UniversitySarbajit Mukherjee - Roswell Park Comprehensive Cancer Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.41(16_suppl), pp.3509-3509
- DOI
- 10.1200/JCO.2023.41.16_suppl.3509
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 06/01/2023
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696539102771
Metrics
6 Record Views